Consistency matters.
Continue to choose CARBAGLU.
![](/wp-content/uploads/2022/03/icon-choose-carbaglu.jpg)
CARBAGLU is the first FDA-approved medication indicated in pediatric and adult patients as:
- Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to
N-acetylgutamate synthase (NAGS) deficiency. - Maintenance therapy for the treatment of chronic hyperammonemia due to N-acetylgutamate synthase (NAGS) deficiency.
- Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA).